Filter By Category
Archives
Share on -
ATUVECICLIB
Generic Name: ATUVECICLIB
ABSTRACT -
Atuveciclib (BAY-1143572) is an investigational small-molecule inhibitor of PTEFb/CDK9. It is designed to interfere with transcriptional regulation in cancer cells and has been studied in oncology research. The compound has molecular formula C18H18FN5O2S.
This document is for structured API information only. It is not a prescribing guide. Clinical use, if any, must follow the approved local label, trial protocol, and specialist medical supervision.
DOSAGE -
- Dosage should be determined only by a qualified oncology professional.
- No routine approved dosing regimen is established for public use.
- Clinical-trial dosing must follow protocol-defined monitoring and dose-modification rules.
- Do not use outside specialist-supervised research.
SIDE EFFECTS-
Possible side effects and safety concerns include:
- Nausea, vomiting, diarrhea, or appetite loss
- Fatigue, headache, dizziness, or weakness
- Blood-count changes such as neutropenia or anemia
- Liver enzyme elevations or electrolyte abnormalities may occur
- Serious infection risk may increase with myelosuppression.
ALLERGIC REACTIONS -
Hypersensitivity to Atuveciclib or related compounds/products may occur. Symptoms may include:
- Immediate urticaria or generalized rash
- Facial, lip, tongue, or throat swelling
- Wheezing or breathing difficulty
- Dizziness, collapse, or anaphylaxis
Important: Patients who develop an allergic reaction to Atuveciclib should seek immediate medical attention and inform all future healthcare providers of the allergy.
DRUG INTERACTIONS-
Atuveciclib may interact with certain medicines, protocols, vaccines, clinical conditions, or procedures. Caution is needed with:
- Other anticancer therapies can increase overlapping toxicity.
- Medicines affecting hepatic metabolism may require protocol review.
- Live vaccines should generally be avoided during significant immune suppression.
- Herbal supplements and over-the-counter medicines should be disclosed.
Patients should inform healthcare providers about all prescription medicines, over-the-counter medicines, herbal products, vaccines, and supplements they are using.
PREAUTIONS–
- Monitor complete blood counts, liver function, and clinical status.
- Assess infection risk and performance status before treatment.
- Use contraception where embryo-fetal risk may apply.
- Use caution in hepatic impairment or severe comorbid disease.
WARNINGS –
- Investigational CDK9 inhibitor: not approved for routine therapy.
- Fever with low white blood cells, severe diarrhea, or allergic reaction requires urgent care.
- May cause fetal harm based on anticancer mechanism.
- Keep out of reach of children.
Share on -
. Developed by